DUBLIN–(BUSINESS WIRE)–The “Global Human Vaccines Market (2022-2027) by Technology, Type, Disease Indication, End-Users, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
The Global Human Vaccines Market is estimated to be USD 62.16 Bn in 2022 and is expected to reach USD 89.16 Bn by 2027, growing at a CAGR of 7.48%.
Market Dynamics
Drivers
- Growing Prevalence of Emerging and Re-Emerging Infectious Diseases
- Increasing Focus on Immunization Programs
- Growing Government Support for Vaccine Development
- Increasing Industry Initiatives to Enhance Vaccine R&D
Restraints
- High Cost of Vaccine Development
- Low Purchasing Power in Developing Countries
Opportunities
- High Growth Prospects in Emerging Markets
- Focus on Therapeutic Vaccines
- Use of Adjuvants in Vaccines
Challenges
- Inequitable Access to Vaccines
Market Segmentations
The Global Human Vaccines Market is segmented based on Technology, Type, Disease Indication, End-Users, and Geography.
- By Technology, the market is classified into Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
- By Type, the market is classified into Monovalent Vaccines and Multivalent Vaccines.
- By Disease Indication, the market is classified into Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, DTP, Polio, and Covid-19.
- By End-Users, the market is classified into Pediatric Vaccines and Adult Vaccines.
- By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.
Countries Studied
- America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Ansoff Analysis
The report presents a detailed Ansoff matrix analysis for the Global Human Vaccines Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
The analyst analyses the Global Human Vaccines Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Human Vaccines Market, By Technology
7 Global Human Vaccines Market, By Type
8 Global Human Vaccines Market, By Disease Indication
9 Global Human Vaccines Market, By End-Users
10 Americas’ Human Vaccines Market
11 Europe’s Human Vaccines Market
12 Middle East and Africa’s Human Vaccines Market
13 APAC’s Human Vaccines Market
14 Competitive Landscape
15 Company Profiles
16 Appendix
Companies Mentioned
- Bavarian Nordic AS
- Bharat Biotech International Ltd.
- Biological E Ltd.
- CSL LTD.
- Daiichi Sankyo Company Ltd.
- Dynavax Technologies Corp.
- Emergent BioSolutions, Inc.
- GSK PLC
- Incepta Pharma Ltd.
- Indian Immunologicals Ltd.
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co, Inc.
- Mitsubishi Chemical Group Corp.
- Novavax, Inc.
- Panacea Biotec
- Pfizer, Inc.
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
- Shenzhen Kangtai Biological Products Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Valneva USA, Inc.
- Zhi Fei Biological
For more information about this report visit https://www.researchandmarkets.com/r/sbuq3u
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900